Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients.

Episode Summary

Episode 264: All About Hormone Replacement Therapy

Dr. Warwick Bishop, a cardiologist and CEO of the Healthy Heart Network, hosts Dr. V, an OBGYN from North Carolina with over 20 years of clinical experience. This episode explores hormone replacement therapy (HRT) for women transitioning through menopause, focusing on cardiovascular risks, appropriate candidates, and the evolution of medical understanding following the landmark Women's Health Initiative study.

Key Takeaways:

• The Women's Health Initiative study (early 2000s) initially showed increased heart attack and stroke risk in HRT users, but later analysis revealed the studied population was older with pre-existing cardiovascular risk factors, leading to more nuanced recommendations.

• HRT should only be used at the lowest effective dose for the shortest duration necessary, typically during perimenopause and early menopause when symptoms are most severe, not as long-term preventive therapy.

• Women with a history of heart attack, stroke, or clotting disorders (DVT/PE) are not candidates for HRT due to increased cardiovascular and thromboembolic risks.

• Lifestyle interventions, particularly regular exercise, significantly reduce the severity of menopausal symptoms like hot flashes, potentially reducing the need for HRT altogether.

• HRT candidates are women experiencing moderate to severe symptoms such as debilitating hot flashes, night sweats disrupting sleep, or significant mood changes (anxiety/depression) during perimenopause.

• Vaginal estrogen therapy for symptoms like vaginal dryness is preferable to systemic HRT because it delivers medication locally without exposing the entire body to estrogen.

• While HRT can support bone density, it is not first-line therapy for osteoporosis; other medications with fewer risk factors are available and preferred.

• Resuming HRT after discontinuing it for over one year carries increased risks and is generally not recommended, making timing of initiation critical.

• The dosage in HRT is significantly lower than in birth control pills, and some women who cannot take oral contraceptives may be candidates for low-dose HRT under close medical supervision.

• Treatment decisions must be highly individualized and customized through collaboration with an OBGYN, balancing symptom relief against cardiovascular, thrombotic, and cancer risks specific to each patient.